Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed


GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration and a generic Advair launch this year was now "highly unlikely".



from Biotech News